Mounjaro and Zepbound arrive in different boxes, in different colors, with different paperwork folded inside. They are the same medicine. Both are tirzepatide, both come from the same manufacturer, and both are injected under the skin once a week. Nearly everything pharmacological is shared between them, and nearly everything written around the molecule, the approved uses, the studied populations and one cardiovascular indication, belongs to one label and not the other.
That makes this pairing unusual among medicine comparisons. There is no which is better question here, because there are not two medicines to rank. What a person meeting both names actually needs is a clear picture of what each label is approved for, what is identical underneath both of them, and why almost none of it changes the day to day work of taking a weekly injection well. The semaglutide pair works the same way and has its own guide in Ozempic vs Wegovy: Same Molecule, Different Rules.
One molecule, two brand names
Tirzepatide is the active ingredient in both products, and it does one distinctive thing: it activates both the GIP receptor and the GLP-1 receptor. That dual action is what separates it from the GLP-1 receptor agonists that came before it, and it is identical whether the box says Mounjaro or Zepbound. The injection cadence is identical too: subcutaneous, once weekly, on a day of the week the person taking it and their prescriber settle on.
The two labels also carry the same boxed warning, the FDA's most serious class of warning, about thyroid C-cell tumors observed in rats, and the same contraindication for people with a personal or family history of medullary thyroid cancer or MEN 2. That warning deserves its own careful reading rather than a summary here, and it has one in The Boxed Warning on Your GLP-1 Label, Explained. For this article the relevant point is simpler: on the question of the warning, the two labels do not differ from each other at all.
What the Mounjaro label is approved for
Mounjaro's approved uses sit in diabetes care. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. That pediatric population is a real distinction: Mounjaro is the one of the two names with an approved use in children.
The label also carries something newer. Mounjaro is indicated to reduce the risk of major adverse cardiovascular events, defined in the label as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in adults with type 2 diabetes who are at high risk for these events. This is new territory for tirzepatide, and it is worth being precise about what it is: a regulator's record that a specific trial population was studied and a specific outcome was counted, not a statement that one molecule outranks another. How to read indications of this kind honestly, including why an absence on a label is not a verdict, is the whole subject of GLP-1s and the Heart: What the Outcome Trials Showed.
What the Zepbound label is approved for
Zepbound's approved uses sit on the weight side of the picture. It is indicated to reduce excess body weight and maintain that reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. It is also indicated to treat moderate to severe obstructive sleep apnea in adults with obesity, an indication that stands on its own trials, covered in Zepbound and Sleep Apnea: What the Indication Covers.
Zepbound carries no cardiovascular indication, and the paragraph above explains why that absence should not be read as a ranking. The label also states a limitation of use plainly: coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended. That limitation states plainly what is easy to get wrong when more than one product is in the picture: medicines from this class are not stacked on one another. Any question about it belongs with a prescriber.
The dose ladder is identical
Below the indications, the two labels converge again. Both products start at 2.5 mg once weekly, and both labels say the same thing about that dose: it is for treatment initiation and is not approved as a maintenance dosage. Both escalate in 2.5 mg increments after at least 4 weeks on the current dose, which is how the familiar ladder of 2.5, 5, 7.5, 10, 12.5 and 15 mg builds itself, one month at a time.
The ceilings differ slightly. Mounjaro's maximum dosage is 15 mg weekly in adults and 10 mg weekly in pediatric patients. Zepbound's maximum is 15 mg weekly for all of its indications, and its label states that safety and effectiveness have not been established in pediatric patients. Zepbound's maintenance dosages also differ by indication: 5, 10 or 15 mg for weight reduction, but 10 or 15 mg for obstructive sleep apnea. Those are facts about paperwork, not about strength: the same 10 mg dose means the same thing under either name. Where a person lands on the ladder is a prescriber's call, made on tolerance and response, and never a reader's project.
GLP 1 Tracker AppLog every tirzepatide dose with the date, the site and a note for the week. The ladder is the same under either name, and so is the record.
Get the app
Missed doses, moved shot days
The missed-dose rules are word for word the same. If a weekly dose is missed, take it as soon as possible within 4 days, meaning 96 hours, of the scheduled time. Past 4 days, the instruction is to skip the missed dose and take the next one on the regularly scheduled day. Never take a double dose to catch up.
Moving the shot day is allowed under the same logic. The day of weekly administration can be changed, as long as the doses on either side of the change are separated by at least 3 days, or 72 hours. Someone who normally injects on Monday and needs to move to Thursday clears that bar comfortably; a move to Wednesday does not, and waits a week. All of this is label mechanics, and any real-world tangle, several missed doses, a gap that stretches, a question about restarting, belongs to the prescriber rather than to improvisation.
What this means for the log you keep
Here is the most useful sentence this comparison produces: because the molecule and the ladder are the same, the tracking is the same. A dose log, a weight trend, injection site notes and a side effect diary kept under one brand name stay fully meaningful if the name on the box ever changes. The week count, the dose step, the pattern of how the week after a shot felt, all of it carries across without translation. The practical side of moving between medicines, including what changes and what does not, is covered in Switching GLP-1 Medications: Tracking Through the Transition.
The two names keep their own tracking pages on this site, because the goals people bring to them differ even when the molecule does not. Mounjaro Tracker: Making Sense of Weekly Tirzepatide is written around the diabetes rhythm, and Zepbound Tracker: Shots, Weight and the Long Game around the weight trend and the long time horizon. Which one a person is prescribed comes down to the indication that fits them, the judgment of their prescriber and what their coverage allows, and nothing in this article is a reason to second-guess any of that. What the comparison does tell you is that the habit of recording each dose faithfully is identical either way, and worth building regardless of which box the pen came from.
Frequently asked questions
Are Mounjaro and Zepbound the same drug?
They contain the same active molecule, tirzepatide, made by the same manufacturer and injected under the skin once weekly. What differs is the approved uses: Mounjaro is labeled for type 2 diabetes in adults and pediatric patients 10 and older, plus cardiovascular risk reduction in adults with type 2 diabetes, while Zepbound is labeled for weight management and for obstructive sleep apnea in adults with obesity. Which one someone takes is a prescriber decision.
Do Mounjaro and Zepbound have the same dose schedule?
Yes. Per the prescribing information, both start at 2.5 mg once weekly, a dose intended only for treatment initiation and not approved as a maintenance dosage, and both increase in 2.5 mg increments after at least 4 weeks on the current dose. The maximum is 15 mg weekly in adults, though Mounjaro caps pediatric patients at 10 mg. Zepbound maintenance dosages differ by indication: 5, 10 or 15 mg for weight reduction, 10 or 15 mg for obstructive sleep apnea.
What happens if I miss a weekly tirzepatide dose?
The rule is identical for both products. Take the missed dose as soon as possible if it is within 4 days, meaning 96 hours, of the scheduled time. If more than 4 days have passed, skip it and take the next dose on the regular day. The day of weekly administration can be changed as long as at least 3 days, or 72 hours, separate two doses. Doubled doses are never the answer, and specific situations belong with the prescriber.
Does Zepbound have a cardiovascular indication like Mounjaro?
No. Mounjaro carries an indication to reduce the risk of major adverse cardiovascular events, defined as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, in adults with type 2 diabetes at high risk for these events. Zepbound carries no cardiovascular indication. As this site has covered before, an indication records what was studied and approved for that product, not a ranking of molecules, so the difference is not a verdict on tirzepatide itself.
Will my tracking change if I move between Mounjaro and Zepbound?
No, and that is the practical payoff of a shared molecule. The ladder, the weekly rhythm, the missed-dose window and the shot-day rules are identical, so a dose log, a weight trend and side effect notes kept under one brand stay meaningful if the name on the box ever changes. A tracker that records the dose taken, the date and how the week felt needs no adjustment at all.